Dr Paul Kelly

Managing Partner



Dr Paul Kelly - Managing Partner at OneVentures, leading Australian Venture Capital firm

Deal lead

Hatchtech | Vaxxas | Clinical Genomics | Prota Therapeutics | BiVACOR Inc | Blade Therapeutics


Sydney, AU


Gemini Genomics (Nasdaq:GMNI), merged with Sequenom (Nasdaq:SQNM) in 2001 | Atomera (Nasdaq:ATMR) | Agamatrix Inc.

Current board roles

Vaxxas | Clinical Genomics | Find-Me Technologies | Hatchtech | Agamatrix Inc. | Garvan Institute of Medical Research | BiVACOR


Charm Health | MedCenter Solutions | Orchid Cellmark | Gemini Genomics | American Society for Law, Medicine and Ethics


Paul has over 25 years experience in developing and commercialising biomedical innovations in United States, Europe, United Kingdom and Australia.   He has led early-stage and mid-stage companies achieve business results in order to attract funding and transform their ideas, technologies and products into sustainable successful businesses. Paul is currently Chair on the Boards of OneVentures investee companies Vaxxas and Hatchtech and is non-executive director of FindMe Technologies and Clinical Genomics. He is also non-executive director of US based Agamatrix Inc.

Paul joined the OneVentures team in 2009, prior to the launch of OneVenture’s first fund in 2010, after spending 15 years in the UK and USA (mostly in Boston, MA). Prior to joining OneVentures, Paul was CEO of Boston based Medcenter Holdings Inc. an on-line pharmaceutical marketing company, a position he held until December 2007. Previously he served as President and CEO of Orchid Cellmark (Nasdaq:ORCH), at that time the worlds leading provider of genetic testing services, from June 2003 until March 2006. During his tenure at both companies he developed and implemented major operational, financial and strategic restructuring. From 1995 to 2001, Paul served as CEO of Gemini Genomics (Nasdaq:GMNI), a clinical genomics company which he co-founded in 1995 to discover and commercialize novel gene-based targets. At Gemini, Paul positioned the company for one of the UK's largest biotechnology IPOs of the time, completed strategic corporate acquisitions in Sweden and Canada, and negotiated collaborations with some of the world's leading research institutions. In 2001, Paul oversaw the company's successful merger with Sequenom (Nasdaq:SQNM), valuing Gemini at over $250M, after which he served for a short period as Executive Vice President.

Before becoming a biotechnology executive, Paul had a distinguished career as a researcher and physician specializing in endocrinology at St Vincent's Hospital, Sydney, Australia. While serving as a researcher at the Garvan Institute for Medical Research in Sydney, and in his postdoctoral work, Paul authored over 100 scientific publications, largely in genetic epidemiology of common metabolic disorders, which have been published in leading journals such as Nature, New England Journal of Medicine, The Lancet, British Medical Journal and Proceedings of the National Academy of Science.

Paul has co-founded a number of other companies in the health sciences and technology arena, including Atomera Inc (Nasdaq: ATMR), based in Los Gatos, California and AgaMatrix, Inc (a consumer medical device company), based in New Hampshire, USA.

Paul has served on a number of national governmental advisory bodies, as well as on the boards of public and private companies. He served on the Board of Directors of the American Society of Medicine, Law and Ethics from 2005 to 2008. Paul is a graduate of the University of New South Wales where he received his Bachelor of Medicine, Bachelor of Surgery (Hons), and Doctor of Medicine degrees. He is a Fellow of the Australasian College of Physicians. He also serves on the UNSW Medicine Dean's Advisory Group and serves on the Board of Directors of the Garvan Institute of Medical Research.